Longevity Science — March 26, 2026

Top Research Findings

1. New Antiaging Senotherapeutics: Senolytics and Senomorphics

Institution/Source: Dermatology Times | Published ~19 hours ago

A newly published clinical review explores the latest advances in senotherapeutics — a drug class targeting senescent cells that accumulate with age. The piece distinguishes between senolytics (which selectively eliminate senescent cells) and senomorphics (which suppress harmful secretions from those cells without killing them). The article focuses on how these agents are being applied in skin health and wound healing, two of the most clinically accessible domains for testing anti-aging interventions.

Why it matters: Senescent cells are a central driver of tissue dysfunction and inflammaging. Evidence-based senotherapeutic strategies — even at the skin level — may offer early proof-of-concept data to guide systemic aging interventions. The ability to test these compounds in dermatological settings offers a relatively accessible path toward broader clinical validation.

2. Reviewing the Development of Novel Senotherapeutics

Institution/Source: Fight Aging! | Published ~1 week ago (within coverage window)

A detailed review article on fightaging.org surveys the current pipeline of novel senotherapeutic compounds under development. The piece examines why standard senolytic combinations (such as dasatinib + quercetin) have limitations, and why the field is pivoting to more targeted molecules with better tissue penetration and fewer off-target effects. The review underscores that senescent cell clearance via immune-mediated mechanisms is gaining traction as a complement to pharmacological approaches.

Why it matters: As the first generation of senolytics moves through clinical trials, identifying next-generation compounds is critical. This review provides a useful map of where the field is heading — from small-molecule drugs to antibody-drug conjugates targeting senescent cell surface markers.

1 sources

fightaging.org

fightaging.org

3. The Rise of Longevity Medicine Clinics

Institution/Source: Medical Daily | Published ~20 hours ago

A new feature reports on the rapid proliferation of longevity medicine clinics offering biomarker testing, gene therapy consultations, and individualized healthspan protocols. These clinics are moving beyond general wellness into highly personalized interventions: epigenetic clock assessments, continuous glucose monitoring, and VO₂ max optimization protocols are now commonly offered alongside more experimental options.

Why it matters: The clinical infrastructure for longevity medicine is maturing. As more patients access biological age measurements and personalized anti-aging protocols, real-world data on intervention effectiveness is beginning to accumulate outside of formal clinical trials — creating a new layer of observational evidence for the field.

1 sources

medicaldaily.com

medicaldaily.com

Clinical Trials & Intervention Updates

Rapamycin: Evidence Slowly Accumulating, But Human Data Remains Incomplete

Rapamycin (sirolimus) continues to be the most discussed pharmacological longevity candidate. A September 2025 review in Aging journal — still highly relevant to current clinical thinking — summarized that while preclinical evidence in model organisms is robust, none of the human trials to date have directly shown that rapamycin extends life or clearly slows the aging process in healthy adults. Some trials showed modest improvements in subjective well-being, walking speed, and strength metrics.

The landmark PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) remains the most closely watched clinical study. Reported data showed that rapamycin supplementation improved muscle and bone health outcomes in older adults — the first long-term clinical trial to demonstrate any such effect. However, experts note that these endpoints are proxies, not direct longevity measures.

A separate review in Aging concluded: "the data in humans have yet to establish that rapamycin, or its analogues, is a proven seno-therapeutic that can delay aging in healthy older adults."

Practical implication: Rapamycin is being prescribed off-label at longevity clinics in low weekly doses, but patients should understand that the current evidence base does not yet support its routine use outside of supervised clinical settings.

Metformin, NAD+ Precursors, and Senolytics: The Broader Pharmacological Landscape

A comprehensive MDPI review (International Journal of Molecular Sciences, September 2025) mapped the current landscape of repurposed and novel anti-aging pharmacology. Key findings: metformin, rapamycin, NAD+ precursors (NMN and NR), and senolytic compounds have all demonstrated lifespan and/or healthspan extension in model organisms. The review also highlighted AMPK activators and CD38 inhibitors as emerging candidates.

Critically, the authors note a persistent gap: most evidence comes from animal models, and human trials are at early stages. The TAME trial (Targeting Aging with Metformin), still ongoing, is expected to be among the first trials powered to detect effects on aging itself rather than individual diseases.

Practical implication: Watch for TAME trial updates in mid-2026, which could shift the evidence bar significantly for metformin as a longevity drug.

Industry & Biotech Watch

Global Longevity Biotech & Senolytic Therapeutics Market Report Released

Source: OpenPR / HTF Market Intelligence | Published ~20 hours ago

A new 143-page global market analysis covering the longevity biotech and senolytic therapeutics sector has been released by HTF Market Intelligence. The report identifies Calico Labs and Altos Labs as major sector anchors, while mapping out an expanding competitive landscape of smaller players developing senolytic drugs, epigenetic reprogramming platforms, and AI-driven aging diagnostics. The market study tracks product pipelines, regulatory pathways, and geographic expansion plans across the sector.

Why it matters: Market intelligence reports like this one reflect growing institutional investor interest in longevity biotech — signaling that capital is continuing to flow into the sector even as the first generation of clinical results remains mixed.

Biotech Stocks and Longevity Investing: Key Trends

Source: Newsweek | Published ~4 days ago (within coverage window)

Newsweek this week published a longevity investing overview noting that biotech stocks surged in 2025, driven partly by FDA approvals and M&A activity in the aging-adjacent sector. The piece tracks how longevity investing has evolved beyond pure-play anti-aging startups into broader healthspan-focused diagnostics, wearables, and therapeutics companies. Venture capital deployment into longevity-related platforms shows no sign of slowing heading into mid-2026.

Deep Dive: Intervention Evidence Check — Senolytics (Dasatinib + Quercetin)

The most-discussed intervention class this week following two fresh senotherapeutics publications is the senolytic drug combination, particularly dasatinib + quercetin (D+Q) — the most clinically studied senolytic regimen.

What human data exists:

• Multiple Phase 1/2 trials have demonstrated that D+Q can reduce circulating senescent cell burden (measured by p16/p21 markers) in humans.
• A trial in patients with idiopathic pulmonary fibrosis showed improvements in physical function measures after D+Q treatment.
• Small trials in diabetic kidney disease and frailty populations suggest tolerability and some biomarker-level efficacy.
• Unity Biotechnology's senolytic trials in osteoarthritis (targeting senescent cells in joints) have shown mixed clinical results, with one Phase 2 trial failing its primary endpoint.

What remains speculative:

• Whether senolytic treatment at intermittent doses translates into measurable healthspan or lifespan extension in otherwise healthy humans.
• The optimal dosing interval, tissue targeting, and long-term safety profile remain poorly characterized.
• Quercetin as a standalone supplement (widely available OTC) has no robust clinical trial evidence supporting longevity benefits at typical consumer doses.

What readers should know before trying it:

• Dasatinib is a chemotherapy drug with real risks (immunosuppression, cardiac toxicity) and requires a physician's prescription and monitoring.
• Quercetin supplements are generally safe at low doses but have limited bioavailability.
• Off-label D+Q protocols are being offered at some longevity clinics; anyone considering this should engage a physician with expertise in the current clinical evidence.

What to Watch Next

• TAME trial (Targeting Aging with Metformin): Expected to release interim data in mid-2026. This is the first trial powered to test a drug's effect on aging itself as a composite endpoint — a potential landmark result for the field.
• PEARL trial extended follow-up data: The rapamycin PEARL trial's longer-term follow-up results are anticipated. Bone and muscle findings were promising; cardiovascular and immune safety data over 12+ months will be critical.
• Next-generation senolytic pipeline: Watch for IND filings and Phase 1 results from companies developing antibody-drug conjugates and CAR-T approaches targeting senescent cells — these could represent a step-change over small-molecule senolytics.
• Epigenetic reprogramming clinical data: Altos Labs and Retro Biosciences are both advancing partial reprogramming platforms toward human studies. Any clinical readout from these programs would represent a major news event in longevity science.

Reader Action Items

1. Ask your doctor about biological age testing. Epigenetic clocks (e.g., GrimAge, DunedinPACE) are now available through longevity clinics and some direct-to-consumer platforms. Understanding your biological vs. chronological age provides a meaningful baseline if you're considering lifestyle or pharmacological interventions. The rise of longevity medicine clinics means access is improving rapidly.

2. Follow the TAME trial closely. Metformin is inexpensive, widely prescribed for Type 2 diabetes, and has a long safety record. If the TAME trial returns positive results, it could become the first approved anti-aging intervention with a large evidence base. Discuss metformin's risk/benefit profile with your physician now if you're in a relevant age group.

3. Be cautious with off-label rapamycin. Despite growing media coverage of rapamycin as a longevity drug, current human evidence does not yet confirm life extension or aging delay in healthy adults. If you are considering it, insist on clinician supervision, regular lab monitoring, and an honest risk discussion — the immunosuppressive effects are not trivial.